Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.

Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA.

Blood Transfus. 2019 Aug 5:1-10. doi: 10.2450/2019.0083-19. [Epub ahead of print]

2.

Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.

Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA.

Vox Sang. 2019 Apr;114(3):237-246. doi: 10.1111/vox.12760. Epub 2019 Mar 18.

PMID:
30883804
3.

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.

Martin A, Lavoie L, Goetghebeur M, Schellenberg R.

Transfus Med. 2013 Feb;23(1):55-60. doi: 10.1111/j.1365-3148.2012.01201.x. Epub 2012 Nov 20.

4.
5.

Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.

Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K.

Clin Ther. 2014 Nov 1;36(11):1616-24. doi: 10.1016/j.clinthera.2014.08.007. Epub 2014 Sep 16.

6.

Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.

Kearns S, Kristofek L, Bolgar W, Seidu L, Kile S.

J Manag Care Spec Pharm. 2017 Apr;23(4):400-406. doi: 10.18553/jmcp.2017.23.4.400.

7.

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies.

Shabaninejad H, Asgharzadeh A, Rezapour A, Rezaei N.

Med J Islam Repub Iran. 2017 Dec 17;31:94. doi: 10.14196/mjiri.31.94. eCollection 2017.

8.

Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.

Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, Tajahmady A, Thomas C, Suarez F, Pellier I, Hermine O, Aladjidi N, Mahlaoui N, Fischer A; French PID study group CEREDIH.

Clin Exp Immunol. 2010 May;160(2):240-5. doi: 10.1111/j.1365-2249.2009.04079.x. Epub 2009 Dec 16.

9.

Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Perraudin C, Bourdin A, Spertini F, Berger J, Bugnon O.

J Clin Immunol. 2016 Jul;36(5):502-10. doi: 10.1007/s10875-016-0288-z. Epub 2016 May 2.

PMID:
27139500
10.

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".

Bienvenu B, Cozon G, Hoarau C, Pasquet M, Cherin P, Clerson P, Hachulla E, Crave JC, Delain JC, Jaussaud R.

Orphanet J Rare Dis. 2016 Jun 22;11(1):83. doi: 10.1186/s13023-016-0452-9.

11.

Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.

Stein MR, Koterba A, Rodden L, Berger M.

Postgrad Med. 2011 Sep;123(5):186-93. doi: 10.3810/pgm.2011.09.2474.

PMID:
21904101
12.

Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.

Bezrodnik L, Gómez Raccio A, Belardinelli G, Regairaz L, Díaz Ballve D, Seminario G, Moreira I, Riganti C, Cantisano C, Díaz H, Di Giovanni D.

J Clin Immunol. 2013 Oct;33(7):1216-22. doi: 10.1007/s10875-013-9916-z. Epub 2013 Jul 12.

PMID:
23846854
13.

Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.

Fu LW, Song C, Isaranuwatchai W, Betschel S.

Ann Allergy Asthma Immunol. 2018 Feb;120(2):195-199. doi: 10.1016/j.anai.2017.11.002.

PMID:
29413344
14.

Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.

Lazzaro C, Lopiano L, Cocito D.

Neurol Sci. 2014 Jul;35(7):1023-34. doi: 10.1007/s10072-014-1632-9. Epub 2014 Jan 28.

15.

Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.

Haddad É, Barnes D, Kafal A.

Transfus Apher Sci. 2012 Jun;46(3):315-21. doi: 10.1016/j.transci.2012.03.022. Epub 2012 Apr 12. Review.

PMID:
22503304
16.

An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland.

Pollock RF, Meckley LM.

Clinicoecon Outcomes Res. 2018 Apr 10;10:223-229. doi: 10.2147/CEOR.S155641. eCollection 2018.

17.

[Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].

Maroto Hernando M, Soler Palacín P, Martin Nalda N, Oliveras Arenas M, Español Boren T, Figueras Nadal C.

An Pediatr (Barc). 2009 Feb;70(2):111-9. doi: 10.1016/j.anpedi.2008.11.011. Epub 2009 Feb 3. Spanish. Erratum in: An Pediatr (Barc). 2010 Mar;72(3):237-8.

18.

Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.

Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, Martín-Nalda A, Oliveras M, Martinez-Cutillas J, Figueras C.

J Clin Immunol. 2014 Nov;34(8):1015-7. doi: 10.1007/s10875-014-0096-2. Epub 2014 Sep 5.

PMID:
25190197
19.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

20.

Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.

Bamrungsawad N, Chaiyakunapruk N, Upakdee N, Pratoomsoot C, Sruamsiri R, Dilokthornsakul P.

Pharmacoeconomics. 2015 May;33(5):521-31. doi: 10.1007/s40273-015-0269-8.

PMID:
25774016

Supplemental Content

Support Center